The PNPLA3 I148M variant is associated with transaminase elevations in type 2 diabetes patients treated with basal insulin peglispro

Performing the Exact Test of Hardy-Weinberg Proportion for Multiple Alleles

Guo, S., & Thompson, E. A. (1992) · Biometrics · doi:10.2307/2532296 · Cited by 4,854 · see citing works

Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416 · see citing works

Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study

Williams, C. D., Stengel, J. Z., Asike, M., Torres, D. M., Shaw, J. C., Contreras, M., Landt, C. L., & Harrison, S. A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.09.038 · Cited by 2,146 · see citing works

The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology

Chalasani, N., Younossi, Z. M., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K. J., Charlton, M., & Sanyal, A. J. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.04.001 · Cited by 1,770 · see citing works

The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis

Ascha, M. S., Hanouneh, I. A., Lopez, R., Tamimi, T. A.-R., Feldstein, A. F., & Zein, N. N. (2010) · Hepatology · doi:10.1002/hep.23527 · Cited by 1,296 · see citing works

Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease

Kozlitina, J., Smagris, E., Stender, S., Nordestgaard, B. G., Zhou, H. H., Tybjærg-Hansen, A., Vogt, T. F., Hobbs, H. H., & Cohen, J. C. (2014) · Nature Genetics · doi:10.1038/ng.2901 · Cited by 1,234 · see citing works

The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent

Mancina, R. M., Dongiovanni, P., Petta, S., Pingitore, P., Meroni, M., Rametta, R., Borén, J., Montalcini, T., Pujia, A., Wiklund, O., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.032 · Cited by 676 · see citing works

A Sequence Variation (I148M) in PNPLA3 Associated with Nonalcoholic Fatty Liver Disease Disrupts Triglyceride Hydrolysis

He, S., McPhaul, C., Li, J. Z., Garuti, R., Kinch, L. N., Grishin, N. V., Cohen, J. C., & Hobbs, H. H. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.064501 · Cited by 604 · see citing works

High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels

Portillo-Sanchez, P., Bril, F., Maximos, M., Lomonaco, R., Biernacki, D., Orsak, B., Subbarayan, S., Webb, A., Hecht, J., & Cusi, K. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1966 · Cited by 503 · see citing works

Heritability of Nonalcoholic Fatty Liver Disease

Schwimmer, J. B., Celedon, M. A., Lavine, J. E., Salem, R. M., Campbell, N. V., Schork, N. J., Shiehmorteza, M., Yokoo, T., Chavez, A. D., Middleton, M. S., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.01.050 · Cited by 464 · see citing works

The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study

Bhala, N. B., Angulo, P., van der Poorten, D., Lee, E., Hui, J. M., Saracco, G. M., Adams, L. A., Charatcharoenwitthaya, P., Topping, J. H., Bugianesi, E., et al. (2011) · Hepatology · doi:10.1002/hep.24491 · Cited by 450 · see citing works

Adipose Triglyceride Lipase: Function, Regulation by Insulin, and Comparison With Adiponutrin

Kershaw, E. E. (2006) · Diabetes · doi:10.2337/diabetes.55.1.148 · Cited by 386 · see citing works

Ethnic differences in hepatic steatosis

Guerrero, R., Vega, G. L., Grundy, S. M., & Browning, J. D. (2008) · Hepatology · doi:10.1002/hep.22726 · Cited by 365 · see citing works

PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells

Pirazzi, C., Valenti, L. V. C., Motta, B. M., Pingitore, P., Hedfalk, K., Mancina, R. M., Burza, M. A., Indiveri, C., Ferro, Y., Montalcini, T., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu121 · Cited by 363 · see citing works

Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk

Holmen, O. L., Zhang, H., Fan, Y., Hovelson, D. H., Schmidt, E. M., Zhou, W., Guo, Y., Zhang, J., Langhammer, A., Løchen, M., et al. (2014) · Nature Genetics · doi:10.1038/ng.2926 · Cited by 302 · see citing works

PNPLA3 I148M polymorphism and progressive liver disease

Dongiovanni, P. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i41.6969 · Cited by 252 · see citing works

Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function

Pingitore, P., Pirazzi, C., Mancina, R. M., Motta, B. M., Indiveri, C., Pujia, A., Montalcini, T., Hedfalk, K., & Romeo, S. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2013.12.006 · Cited by 212 · see citing works

Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study

Krawczyk, M. J., Rau, M., Schattenberg, J. M., Bantel, H., Pathil, A., Demir, M., Kluwe, J., Boettler, T., Lammert, F., & Geier, A. (2016) · Journal of Lipid Research · doi:10.1194/jlr.p067454 · Cited by 204 · see citing works

The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans

Luukkonen, P. K., Zhou, Y., Hyötyläinen, T., Leivonen, M., Arola, J. T., Orho‐Melander, M., Orešič, M., & Yki‐Järvinen, H. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.07.045 · Cited by 178 · see citing works

The dual and opposite role of the TM6SF2‐rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: A meta‐analysis

Pirola, C. J., & Sookoian, S. C. (2015) · Hepatology · doi:10.1002/hep.28142 · Cited by 171 · see citing works

PNPLA 3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease

Shen, J., Wong, G. L., Chan, H. L., Chan, R., Chan, H., Chu, C. W., Cheung, B., Yeung, D. K., Li, L. S., Sea, M. M.-M., et al. (2014) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12656 · Cited by 159 · see citing works

Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis

Dongiovanni, P., Romeo, S., & Valenti, L. V. C. (2015) · BioMed Research International · doi:10.1155/2015/460190 · Cited by 150 · see citing works

PNPLA3 I148M Variant Influences Circulating Retinol in Adults with Nonalcoholic Fatty Liver Disease or Obesity ,

Mondul, A. M., Mancina, R. M., Merlo, A., Dongiovanni, P., Rametta, R., Montalcini, T., Valenti, L. V. C., Albanes, D., & Romeo, S. (2015) · Journal of Nutrition · doi:10.3945/jn.115.210633 · Cited by 115 · see citing works

Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial

Scorletti, E., West, A. L., Bhatia, L. S., Hoile, S. P., McCormick, K. G., Burdge, G. C., Lillycrop, K. A., Clough, G. F., Calder, P. C., & Byrne, C. D. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.07.036 · Cited by 108 · see citing works

Novel PEGylated Basal Insulin LY2605541 Has a Preferential Hepatic Effect on Glucose Metabolism

Moore, M. C., Smith, M. S., Sinha, V. P., Beals, J. M., Michael, M. D., Jacober, S. J., & Cherrington, A. D. (2013) · Diabetes · doi:10.2337/db13-0826 · Cited by 84 · see citing works

Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5

Buse, J. B., Rodbard, H. W., Serrano, C. T., Luo, J., Iványi, T., Bue‐Valleskey, J. M., Hartman, M. L., Carey, M. A., & Chang, A. M. (2015) · Diabetes Care · doi:10.2337/dc15-1531 · Cited by 82 · see citing works

PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery

Krawczyk, M. J., Jiménez-Agüero, R., Alústiza, J. M., Emparanza, J. I., Perugorria, M. J., Bujanda, L., Lammert, F., & Bañales, J. M. (2016) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2016.06.004 · Cited by 75 · see citing works

Reproducibility of hepatic fat fraction measurement by magnetic resonance imaging

Mashhood, A., Railkar, R. A., Yokoo, T., Levin, Y. S., Clark, L., Fox‐Bosetti, S., Middleton, M. S., Riek, J. K., Kauh, E. A., Dardzinski, B. J., et al. (2012) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.23928 · Cited by 74 · see citing works

Epidemiology and risk factors of nonalcoholic fatty liver disease (NAFLD)

Duseja, A., & Chalasani, N. (2013) · Hepatology International · doi:10.1007/s12072-013-9480-x · Cited by 74 · see citing works

PNPLA3 I148M variant and hepatocellular carcinoma: A common genetic variant for a rare disease

Valenti, L. V. C., Dongiovanni, P., Corradini, S. G., Burza, M. A., & Romeo, S. (2013) · Digestive and Liver Disease · doi:10.1016/j.dld.2012.12.006 · Cited by 67 · see citing works

Steady‐state pharmacokinetics and glucodynamics of the novel, long‐acting basal insulin LY2605541 dosed once‐daily in patients with type 2 diabetes mellitus

Sinha, V. P., Howey, D. C., Choi, S. L., Mace, K. F., & Heise, T. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12222 · Cited by 61 · see citing works

Adiponutrin gene is regulated by insulin and glucose in human adipose tissue

Moldes, M., Beauregard, G., Faraj, M., Peretti, N., Ducluzeau, P., Laville, M., RABASA-LHORET, R. P. R., Vidal, H., & Clément, K. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02229 · Cited by 61 · see citing works

The Genetic Variant I148M inPNPLA3Is Associated With Increased Hepatic Retinyl-Palmitate Storage in Humans

Kovářová, M., Königsrainer, I., Königsrainer, A., Machicao, F. E., Häring, H., Schleicher, E. D., & Peter, A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2978 · Cited by 60 · see citing works

Randomized, double‐blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3

Bergenstal, R. M., Lunt, H., Franek, E., Travert, F., Mou, J., Qu, Y., Antalis, C. J., Hartman, M. L., Rosilio, M., Jacober, S. J., et al. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12698 · Cited by 47 · see citing works

Basal insulin peglispro versus insulin glargine in insulin‐naïve type 2 diabetes: IMAGINE 2 randomized trial

Davies, M. J., Russell-Jones, D. L., Selam, J. L., Bailey, T. S., Kerényi, Z., Luo, J., Bue‐Valleskey, J. M., Iványi, T., Hartman, M. L., Jacobson, J. G., et al. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12712 · Cited by 46 · see citing works

Randomized double‐blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4

Blevins, T., Pieber, T. R., Vega, G. C., Zhang, S., Bastyr, E. J., Chang, A. M., & on behalf of the IMAGINE 4 Investigators (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12696 · Cited by 45 · see citing works

Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes

Cusi, K. J., Sanyal, A. J., Zhang, S., Hoogwerf, B. J., Chang, A. M., Jacober, S. J., Bue-Valleskey, J. M., Higdon, A. N., Bastyr, E. J., Haupt, A., et al. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12751 · Cited by 40 · see citing works

A randomized clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 1

Garg, S. K., Dreyer, M., Jinnouchi, H., Mou, J., Qu, Y., Hartman, M. L., Rosilio, M., Jacober, S. J., Bastyr, E. J., & on behalf of the IMAGINE 1 Trial Investigators (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12738 · Cited by 30 · see citing works

Reduced peripheral activity leading to hepato‐preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes

Mudaliar, S. R. D., Henry, R. R., Ciaraldi, T. P., Armstrong, D. A., Burke, P., Pettus, J., Garhyan, P., Choi, S. L., Knadler, M. P., Lam, E. C. Q., et al. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12753 · Cited by 20 · see citing works

Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trials

Ginsberg, H. N., Cariou, B., Orchard, T. J., Chen, L., Luo, J., Bastyr, E. J., Bue‐Valleskey, J. M., Chang, A. M., Iványi, T., Jacober, S. J., et al. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12754 · Cited by 19 · see citing works

A randomized clinical trial of basal insulin peglispro vs NPH in insulin‐naïve patients with type 2 diabetes: the IMAGINE 6 trial

Grunberger, G., Chen, L., Rodríguez, Á., Tinahones, F. J., Jacober, S. J., Bue‐Valleskey, J. M., & on behalf of the IMAGINE 6 Investigators (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12743 · Cited by 13 · see citing works

Similar HbA1c reduction and hypoglycaemia with variable‐ vs fixed‐time dosing of basal insulin peglispro in type 1 diabetes: IMAGINE 7 study

Garg, S. K., Selam, J. L., Bhargava, A., Schloot, N. C., Luo, J., Zhang, Q., Jacobson, J. G., & Hoogwerf, B. J. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12740 · Cited by 11 · see citing works

Attenuated suppression of lipolysis explains the increases in triglyceride secretion and concentration associated with basal insulin peglispro relative to insulin glargine treatment in patients with type 1 diabetes

Johansen, R. F., Søndergaard, E., Linnebjerg, H., Garhyan, P., Lam, E. C. Q., Pørksen, N. K., Jacober, S. J., & Nielsen, S. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13087 · Cited by 9 · see citing works

Healthy PNPLA3 Risk Allele Carriers Present with Unexpected Body Fat Composition. A Study of One ousand Subjects

Kempińska‐Podhorodecka, A., Krawczyk, M. J., Klak, M., Blatkiewicz, M., Lammert, F., Milkiewicz, P., & Milkiewicz, M. (2014) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-1276 · Cited by 6 · see citing works

Hepato‐preferential insulins: I s this the end, or the end of the beginning?

Russell-Jones, D. L. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12756 · Cited by 5 · see citing works

Reply to “Hepatocellular carcinoma and the Newcastle-upon-Tyne area”

Anstee, Q. M., Jaques, B., Hudson, M., & Reeves, H. L. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.02.017 · Cited by 1 · see citing works

EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).

Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210 · see citing works

EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

(2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 510 · see citing works

Update on NAFLD genetics: From new variants to the clinic

Trépo, E., & Valenti, L. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.02.020 · Cited by 393 · see citing works

Leveraging Human Genetics to Identify Potential New Treatments for Fatty Liver Disease

Romeo, S., Sanyal, A. J., & Valenti, L. V. C. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.12.002 · Cited by 203 · see citing works

Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis

Carlsson, B., Lindén, D., Brolén, G., Liljeblad, M., Bjursell, M., Romeo, S., & Loomba, R. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15738 · Cited by 169 · see citing works

Insulin Resistance Exacerbates Genetic Predisposition to Nonalcoholic Fatty Liver Disease in Individuals Without Diabetes

Barata, L., Feitosa, M. F., Bielak, L. F., Halligan, B. D., Baldridge, A. S., Guo, X., Yerges‐Armstrong, L. M., Smith, A. V., Yao, J., Palmer, N. D., et al. (2019) · Hepatology Communications · doi:10.1002/hep4.1353 · Cited by 60 · see citing works

Novel Insights into the Genetic Landscape of Nonalcoholic Fatty Liver Disease

Taliento, A. E., Dallio, M., Federico, A., Prati, D., & Valenti, L. V. C. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16152755 · Cited by 39 · see citing works

Renaming NAFLD to MAFLD: Could the LDE System Assist in This Transition?

Lonardo, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10030492 · Cited by 38 · see citing works

Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)

Marchesini, G., Bugianesi, E., Burra, P., Marra, F., Miele, L., Alisi, A., Vajro, P., Masarone, M., Petta, S., Persico, M., et al. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.04.028 · Cited by 35 · see citing works

Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)

Marchesini, G., Bugianesi, E., Burra, P., Marra, F., Miele, L., Alisi, A., Vajro, P., Masarone, M., Petta, S., Persico, M., et al. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.04.029 · Cited by 33 · see citing works

Human genetics of steatotic liver disease: insights into insulin resistance and lipid metabolism

Mancina, R. M., Valenti, L. V. C., & Romeo, S. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01394-8 · Cited by 28 · see citing works

Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches

Mahmoudi, S. K., Tarzemani, S., Aghajanzadeh, T., Kasravi, M., Hatami, B., Zali, M. R., & Baghaei, K. (2024) · European journal of medical research · doi:10.1186/s40001-024-01708-8 · Cited by 22 · see citing works

Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)

Associazione Italiana per lo Studio del Fegato (AISF), S. I. D. D. (. A. S. I. D. (. (2021) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-021-01287-1 · Cited by 22 · see citing works

Coding variants in PNPLA3 and TM6SF2 are risk factors for hepatic steatosis and elevated serum alanine aminotransferases caused by a glucagon receptor antagonist

Guzmán, C. B., Duvvuru, S., Akkari, P. A., Bhatnagar, P., Battioui, C., Foster, W. M., Zhang, X. M., Shankar, S. S., Deeg, M. A., Chalasani, N., et al. (2018) · Hepatology Communications · doi:10.1002/hep4.1171 · Cited by 17 · see citing works

Association of PNPLA3 risk variant with steatotic liver disease among lean people with HIV mono-infection

Han, W. M., Apornpong, T., Chuaypen, N., Tangkijvanich, P., & Avihingsanon, A. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.08.017 · Cited by 4 · see citing works

Cell and gene therapeutic approaches in non-alcoholic fatty liver disease

Poudineh, M., Mohammadyari, F., Parsamanesh, N., Jamialahmadi, T., Kesharwani, P., & Sahebkar, A. (2025) · Gene · doi:10.1016/j.gene.2025.149466 · Cited by 3 · see citing works

Molecular mechanisms of metabolic disease-associated hepatic inflammation in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

Zhang, C., Sui, Y., Liu, S., & Yang, M. J. (2023) · Exploration of Digestive Diseases · doi:10.37349/edd.2023.00029 · Cited by 3 · see citing works

Impact of PNPLA3 I148M on Drug‐Induced Hepatocellular Liver Injury: A Systematic Review and Meta‐Analysis

Gatzios, A., Marchandise, L., Hagström, H., Schattenberg, J. M., Rodrigues, R. M., Vanhaecke, T., & Boeckmans, J. (2025) · Liver International · doi:10.1111/liv.70287 · Cited by 2 · see citing works

The Natural History of NAFLD: Environmental vs. Genetic Risk Factors

Valenti, L. V. C., & Pelusi, S. (2020) · Springer eBooks · doi:10.1007/978-3-319-95828-6_7 · Cited by 2 · see citing works

Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes

Cusi, K. J., Sanyal, A. J., Zhang, S., Hoogwerf, B. J., Chang, A. M., Jacober, S. J., Bue-Valleskey, J. M., Higdon, A. N., Bastyr, E. J., Haupt, A., et al. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12751 · Cited by 40 · see citing works

Liver Fat Changes in Patients With Type 2 Diabetes by Presence of Genetic Hepatic Steatosis: A Post Hoc Analysis of SURPASS ‐3 MRI

Cusi, K. J., Gastaldelli, A., Landó, L. F., Sharma, P., Torcello‐Gómez, A., & Rodríguez, Á. (2026) · Liver International · doi:10.1111/liv.70837

759-P: Changes in Liver Fat in Patients with Type 2 Diabetes by Presence of Genetic Hepatic Steatosis in the SURPASS-3 MRI Substudy

Cusi, K. J., Gastaldelli, A., Landó, L. F., LIU, M., Torcello‐Gómez, A., & RODRÍGUEZ, Á. (2023) · Diabetes · doi:10.2337/db23-759-p

The effects of basal insulin peglispro vs. insulin glargine on lipoprotein particles by NMR and liver fat content by MRI in patients with diabetes

Orchard, T. J., Cariou, B., Connelly, M. A., Otvos, J. D., Zhang, S., Antalis, C. J., Iványi, T., & Hoogwerf, B. J. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0555-1 · Cited by 4 · see citing works

PNPLA3 variant I148M is associated with altered hepatic lipid composition in humans

Peter, A., Kovářová, M., Nadalin, S., Cermak, T., Königsrainer, A., Machicao, F. E., Stefan, N., Häring, H., & Schleicher, E. D. (2014) · Diabetologia · doi:10.1007/s00125-014-3310-0 · Cited by 51 · see citing works